| MIAs | multi-institutional arrangements; medically indigent adults |
|---|---|
| MID | maximum inhibiting dilution; mesioincisodistal; midinfarct dementia; minimum infective dose; minimum... |
| MSIS | multi-state information system |
| MUMPS | Massachusetts General Hospital Utility Multi-Programming System |
| DTIC | Dimethyl Triazeno Imidazole Carboxamide ; Alkylating Agent |
| antineoplastic agent, hormonal | Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias. (12 Dec 1998) |
|---|---|
| antineoplastic agent, phytogenic | Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity. (12 Dec 1998) |
| antipsychotic agent | A functional category of neuroleptic drugs that are helpful in the treatment of psychosis and have a capacity to ameliorate thought disorders (e.g., chlorpromazine, haloperidol). See: neuroleptic. Synonym: antipsychotic, major tranquilliser. (05 Mar 2000) |
| antithyroid agent | <pharmacology> Medications which suppress thyroid function. Examples include methimazole and propylthiouracil. (13 Jan 1998) |
| bacteriostatic agent | Any agent that inhibits or retards bacterial growth. Synonym: bacteriostatic agent. (05 Mar 2000) |
| beta-adrenergic blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| beta-adrenergic receptor blocking agent | A class of drugs that compete with beta-adrenergic agonists for available receptor sites; some compete for both b1 and b2 receptors (e.g., propranolol) while others are primarily either b1 (e.g., metoprolol) or b2 blockers; used in the treatment of a variety of cardiovascular diseases where beta-adrenergic blockade is desirable. Synonym: beta-adrenergic receptor blocking agent, beta-adrenoreceptor antagonist, beta-blocker. (05 Mar 2000) |
| biological agent | <microbiology> A disease-causing microorganism or virus, or other toxic biological matter, which is used as a weapon during war. (21 Mar 1998) |
| Bittner agent | <virology> Earlier name, now superseded, for the mouse mammary tumour virus. (18 Nov 1997) |
| blister agent | <chemistry, pharmacology> Refers to a chemical or agent that causes blisters. (09 Oct 1997) |
| blocking agent | A class of drugs that inhibit (block) a biologic activity or process, such as axonal conduction or transmission, or ions across a cell membrane; frequently called "blockers." (05 Mar 2000) |
| bronchoconstrictor agent | Agents causing the narrowing of the lumen of a bronchus or bronchiole. (12 Dec 1998) |
| cardiotonic agent | Agents that have a tonic effect on the heart or increase cardiac output. They may be glycosidic steroids related to digitalis products, sympathomimetic, or other drugs and are used after myocardial infarcts, cardiac surgery, in shock, or in congestive heart failure. (12 Dec 1998) |
| cariogenic agent | Substances conducive to the production of dental caries. (12 Dec 1998) |
| cariostatic agent | Substances that inhibit or arrest dental caries formation. (12 Dec 1998) |